Chart Analysis
ACR Daily Timeframe Chart as of 28 May 2026
Acrux (ASX: ACR) Licenses Lenzetto® Estradiol Spray for Australia Through Gedeon Richter Amendment — Up to A$5.4 Million in Milestone Payments
Australian specialty pharma company Acrux Limited has amended its global licensing agreement with Budapest-listed Gedeon Richter Plc to extend Lenzetto® — a transdermal estradiol spray for menopausal hormone therapy — into the Australian market. The deal could deliver up to A$5.4 million in upfront, regulatory, and commercial milestone payments within two years of launch. Lenzetto® was developed by Acrux using its proprietary Patchless Patch™ delivery technology (invented at Monash University) and is already marketed by Richter in more than 40 countries with global sales of EUR 50 million in 2025. The Australian launch is positioned to address what Acrux describes as a critical shortage of menopause hormone therapy (MHT) products in the domestic market.
What is Lenzetto® and How Does the Deal Work
Lenzetto® is a transdermal estradiol spray used to treat symptoms associated with oestrogen deficiency after menopause, including hot flushes. The product delivers estradiol through the skin via Acrux's Patchless Patch™ technology — a metered-dose spray that forms a drug reservoir on the skin surface, providing consistent hormone delivery without a traditional adhesive patch.
Under the amended agreement, Gedeon Richter will commercialise Lenzetto® in Australia, with Acrux receiving milestone payments structured as an upfront payment plus regulatory and commercial milestones, totalling up to A$5.4 million within two years of the product's Australian launch. The specific payment schedule and individual milestone triggers are commercial-in-confidence.
Richter is a EUR 4.8 billion market capitalisation Hungarian pharmaceutical company with 2025 sales of EUR 2.3 billion, operating Central Europe's largest pharmaceutical R&D hub with a focus on neuropsychiatry and women's healthcare.
Acrux's Pipeline Beyond Lenzetto — Female Testosterone Product
CEO John Warmbrunn framed the Lenzetto® Australian milestone payments as strengthening the company's financial position while it continues to develop its Female Testosterone product — the next pipeline priority. Acrux's broader product portfolio includes Evamist (estradiol spray, US market), Dapsone Gel (acne, US), Lidocaine and Prilocaine Cream, and development-stage programs in efinaconazole (toenail fungal infections), nitroglycerin ointment (anal fissure), and acyclovir cream (cold sores).
Acrux reported FY2025 revenue of approximately A$1.19 million (down 76.6% from A$5.09 million in FY2024) and is currently loss-making. The analyst consensus target price of A$0.23 per Stockopedia sits substantially above the current trading range.
The Australian MHT Shortage Context
The announcement positions the Lenzetto® Australian launch against a backdrop of reported shortages in menopause hormone therapy products domestically. MHT demand has increased significantly in recent years as awareness of menopausal symptoms and treatment options has grown, with supply chain constraints affecting availability of several established products in the Australian market. Lenzetto®'s spray delivery format provides an alternative to patches and oral preparations.
Risks & Considerations
The A$5.4 million figure represents the maximum total of all milestone payments — it is not guaranteed revenue. Individual milestones are tied to regulatory approval and commercial performance thresholds that have not been disclosed. The upfront component has not been quantified separately, and the commercial-in-confidence nature of the terms means the payment structure cannot be independently assessed.
Acrux does not commercialise Lenzetto® itself — Gedeon Richter handles all marketing, distribution, and sales. Acrux's revenue from this arrangement is limited to milestone payments and any ongoing royalties (terms undisclosed), not direct product sales. The company's ability to influence market uptake, pricing, or distribution execution in Australia is limited.
Revenue declined 76.6% in FY2025, and the company is loss-making. The A$5.4 million in potential milestones over two years is material relative to Acrux's current revenue base and market capitalisation (~A$5–7 million), but the timing and certainty of individual payments depends on Richter's regulatory and commercial execution in Australia.
At sub-2-cent price levels, the stock trades with extremely limited liquidity. The +30% announcement-day move represents an absolute change of $0.003 (three-tenths of a cent), and the intraday range of $0.010 to $0.021 (+110% high to close, then 38% reversal) reflects the volatility profile of micro-cap pharma stocks at these price levels.
Key Dates & Timeline
| Date | Event |
|---|---|
| 2025 | Lenzetto® achieves EUR 50 million in global sales across 40+ countries |
| FY2025 | Acrux revenue A$1.19 million (down 76.6%); loss-making |
| 28 May 2026 | Lenzetto® Australian licence amendment announced; share price moved +30.0% |
| Within 2 years of Australian launch | Up to A$5.4 million in milestone payments (upfront + regulatory + commercial) |
| TBC | TGA regulatory submission and approval for Lenzetto® in Australia |
| TBC | Female Testosterone product development milestones |
Price Data
- Previous Close: $0.010
- Close Price (28 May 2026): $0.013
- Change (28 May 2026): +30.0%
- 52-Week Range: $0.009 – $0.024
Notable Price Levels
-
$0.021 — intraday high on announcement day. The stock traded to $0.021 (+110% intraday) before reversing sharply to close at $0.013 — a 38% decline from the session high. This is one of the most severe intraday rejections in this article series, with the stock giving back more than two-thirds of its intraday gains. The wide gap between high ($0.021) and close ($0.013) indicates the initial reaction significantly overshot the market's settled assessment of the deal's value.
-
$0.013 — announcement-day close, sitting in the lower third of the session's range. At $0.013, Acrux's market capitalisation is approximately A$5.3 million — roughly in line with the maximum A$5.4 million in milestone payments, meaning the market is valuing the entire company at approximately one Lenzetto® Australian deal. The analyst consensus target of A$0.23 sits approximately 1,670% above this level.
-
$0.010 — the previous close and the placement price reference for recent activity. The stock had been consolidating in a $0.009–$0.011 range for several months, establishing this as the undisturbed equilibrium. A retracement to $0.010 would unwind the announcement premium entirely.
-
$0.009 — 52-week low and the structural floor of the extended basing range. At this level, the market capitalisation was approximately A$3.7 million — below even a single year's potential milestone payments from the Lenzetto® deal.
Summary
Acrux has amended its licensing agreement with Gedeon Richter to bring Lenzetto® — a transdermal estradiol spray already generating EUR 50 million in annual global sales across 40+ countries — into the Australian market, with up to A$5.4 million in milestone payments to Acrux within two years of launch. The deal addresses a reported shortage of MHT products domestically and strengthens Acrux's financial position as it develops its Female Testosterone pipeline. The announcement coincided with a +30.0% move to $0.013, though the stock traded as high as $0.021 (+110%) before reversing 38% from the session high. At $0.013, the company's market capitalisation of approximately A$5.3 million is roughly equivalent to the maximum milestone value of the deal itself. Milestone payments are conditional on regulatory and commercial outcomes, and Acrux does not directly commercialise the product — Richter handles all marketing and distribution.
This article is for informational purposes only and does not constitute financial advice. Market Flow does not recommend buying or selling any securities. Past performance is not indicative of future results. Readers should conduct their own independent research and consult a licensed financial adviser before making any investment decisions. This content is published in accordance with ASX Market Rules and is not a financial product recommendation.